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a b s t r a c t
The high genetic diversity of HIV-1 impedes high throughput, large-scale sequencing and full-length
genome cloning by common restriction enzyme based methods. Applying novel methods that employ a
high-ﬁdelity polymerase for ampliﬁcation and an unbiased fusion-based cloning strategy, we have
generated several HIV-1 full-length genome infectious molecular clones from an epidemiologically
linked transmission pair. These clones represent the transmitted/founder virus and phylogenetically
diverse non-transmitted variants from the chronically infected individual's diverse quasispecies near the
time of transmission. We demonstrate that, using this approach, PCR-induced mutations in full-length
clones derived from their cognate single genome amplicons are rare. Furthermore, all eight non-
transmitted genomes tested produced functional virus with a range of infectivities, belying the previous
assumption that a majority of circulating viruses in chronic HIV-1 infection are defective. Thus, these
methods provide important tools to update protocols in molecular biology that can be universally
applied to the study of human viral pathogens.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Human immunodeﬁciency virus type 1 (HIV-1) is a human
lentivirus that causes Acquired Immunodeﬁciency Syndrome
(AIDS) and currently infects approximately 30 million people
worldwide, killing 1.3 million people annually (UNAIDS, 2013).
HIV-1 is spread predominantly through heterosexual transmission
in Sub-Saharan Africa, where the health burden is greatest
(UNAIDS, 2013; Dunkle et al., 2008). HIV-1 infection leads to
chronic disease in humans that is able to persist despite a robust
cellular immune response as well as constant antibody-mediated
pressure (Phillips et al., 1991; Richman et al., 2003). HIV-1 evades
immune pressures by generating escape mutations via its high
viral turnover and error-prone reverse transcriptase enzyme, as
well as undergoing latent infection of memory CD4þ T cells (Cofﬁn
and Swanstrom, 2013). Both rapid genetic mutation and latency
also allow HIV-1 to develop resistance and persist against modern
regimens of highly active antiretroviral therapy (Arts and Hazuda,
2012). The genetic diversity of HIV-1, a result of the accumulation
of mutations in the viral genome, means that it exists as a complex
quasispecies of many genetically-distinct viral genomes in
chronically-infected individuals.
Little is known about the biological activity of the many
circulating variants in the plasma of chronically-infected indivi-
duals. Although it is suggested that a majority of proviral inte-
grated genomes comprising the latent reservoir are defective, this
has been poorly characterized within the RNA viral quasispecies
(Sanchez et al., 1997; Eriksson et al., 2013). Research to date
describing the biological and molecular characteristics of HIV-1
from chronically infected individuals has, for the most part, used
isolates grown out of patient plasma in vitro, or laboratory-adapted
clonal strains (Ochsenbauer et al., 2012; Fenton-May et al., 2013).
However, these viruses likely do not accurately represent the
viruses that exist in vivo, as they have been grown and passaged
in culture, which can change their phenotypic properties
(Meyerhans et al., 1989). Accurately measuring the viral character-
istics of full-length HIV-1 genomes derived from the quasispecies
of a chronically-infected individual is important for determining
the ﬁtness of the quasispecies, which may impact pathogenesis
(Fraser et al., 2014). It will also provide a much sought after panel
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of viruses with which to compare Transmitted/Founder (TF)
viruses in transmission studies in order to determine viral require-
ments for transmission (Fraser et al., 2014; Shaw and Hunter,
2012).
In 80% of heterosexual transmission events of HIV-1, a single
TF virus is transmitted and establishes infection in the naïve host
from the diverse quasispecies in the chronically-infected donor
(Wolfs et al., 1992; Wolinsky et al., 1992; Keele et al., 2008;
Derdeyn et al., 2004). In order to determine biological correlates
associated with this genetic bottleneck, it is imperative to compare
the TF virus with full-length viruses present in the donor near the
time of transmission. In the context of transmission studies to
date, no full-length TF virus has been compared to the non-
transmitted full-length genome viruses of the cognate donor
(Shaw and Hunter, 2012). A recent study generated full-length
clones from clonal clusters in chronically-infected individuals
because they hypothesized that the inferred common ancestors
of these clusters encoded persistently replicating viruses in con-
trast to those viruses not in clusters (Parrish et al., 2013). Previous
strategies attempting to clone full-length genomes from isolates
derived from chronically-infected patients failed to produce any
functional genomes prior to rescue by an adapted Envelope gene
(Ndung'u et al., 2001; Ndung'u, 2000).
We suggest here that the lack of knowledge in this area results
from the absence of appropriate methodology to accurately amplify
and clone full-length genomes. The main methodological limitations
of studies to date are the generation of full-length genomes crippled
by PCR-induced mutations from the polymerases used, and depen-
dence on restriction enzyme sites within those sequences in order to
generate clones (Ochsenbauer et al., 2012; Salazar-Gonzalez et al.,
2009; Baalwa et al., 2012). Due to the inherent genetic diversity and
instability of RNA viruses such as HIV-1, manipulation of the genetic
material fromwhich it exists has proven challenging with commonly
used methods. Here, we demonstrate, in the context of an HIV-1
subtype C infected heterosexual transmission pair, a novel method to
amplify and clone full-length infectious molecular clones in a faster,
cheaper, and more accurate manner. Using these methods, we are
able to show that a majority of genomes found in a chronically-
infected individual are in fact functional and display a wide range in
particle infectivity. We also compare for the ﬁrst time, the particle
infectivity of a full-length TF virus with respect to full-length non-
transmitted (NT) viruses from the chronically-infected epidemiolo-
gically linked donor.
Results
Rapid high-ﬁdelity single genome ampliﬁcation of HIV-1 subtype
C near-full-length genomes
Using similar methods as described previously (Salazar-
Gonzalez et al., 2009; Rousseau et al., 2006), but with a newly-
released high ﬁdelity enzyme, Q5 Hot-Start Polymerase (New
England Biolabs), we have ampliﬁed near full-length (NFL) single
genomes by limiting dilution PCR from infected patient plasma
in an acutely-infected linked recipient (Fiebig Stage II, 22 days
post-estimated day of infection) and the chronically-infected
epidemiologically-linked donor partner near the time of the
transmission event (Table 1). Using a slightly modiﬁed master
mix and cycling conditions from those recommended by the
manufacturer (see Materials and methods), we shortened PCR
ampliﬁcation times and decreased the cost of reagents from
previously employed methods using the Roche Expand Long
Template enzyme. The improved ﬁdelity of the Q5 enzyme as
compared to other polymerases is highly advantageous, as single
mutations in the genome can have a signiﬁcant impact on viral
ﬁtness. In limiting dilution PCRs from full-length viral cDNA, we
have also observed that the efﬁciency of NFL PCR was increased,
since samples at the same dilution of cDNA yielded increased
numbers of positive reactions with Q5 than with Expand Long
Template. Using the included GC enhancer, which enhances
polymerase read-through of high GC content templates, DNA yield
was further increased (data not shown). NFL single genome nested
PCR followed by direct Sanger sequencing of 8 NFL genomes
ampliﬁed from a p24þ/Ab plasma sample of the linked recipient
of a heterosexual transmission pair allowed us to determine the TF
sequence based on the consensus of all reads after conﬁrming star-
like phylogeny (as described previously (Salazar-Gonzalez et al.,
2009)) (Fig. 1A).
In conjunction, we ampliﬁed 17 single NFL genomes from the
plasma of the chronically-infected donor near the time of trans-
mission. A maximum likelihood tree of the combined 25 viral
sequences showed that: 1) the pair was epidemiologically linked,
2) subtype was conﬁrmed by phylogenetic clustering with other
known subtype C variants, and 3) the recipient was infected with a
single variant from the donor quasispecies (Fig. 1B). Three of the 17
NFL genomes from the chronically-infected donor's quasispecies
contained either a stop codon or a frameshift mutation in one of
its genes, indicating that these three non-functional genomes
would fail to produce functional virus following infection. The 14
remaining sequences from the donor, as well as the TF of the
recipient, showed intact coding regions with no stop codons,
frameshift mutations or APOBEC3G hypermutation, suggesting
that the these have the potential to produce functional genomes.
The donor's viral population showed extensive genetic diversity
across the whole genome with differences of up to 4.2% between
viruses. In order to determine the functionality of viruses circulat-
ing in a chronically-infected patient, we chose to generate infec-
tious molecular clones (IMCs) for the recipient TF virus genome
and for 8 of the 14 intact amplicons that represented the diversity
of viruses from the chronically-infected donor.
Generation of a TF speciﬁc LTR vector from the linked recipient
A hallmark of retroviruses is that the virion-packaged RNA
genomes do not contain the entire long terminal repeat (LTR), as
the two full LTRs that ﬂank the genome are generated during the
reverse transcription steps following cell entry. The repeated nature
of the LTRs makes it difﬁcult to generate amplicons that contain the
equivalent of the integrated proviral DNA required for cloning a
transcriptionally functional genome. Previous methods for genera-
tion of full-length TF genomes have required a separate RNA
ampliﬁcation of the 50 LTR, followed by complex engineering of virus
LTRs (Ochsenbauer et al., 2012). Since the NFL ampliﬁcation primers
cover a portion of the viral LTR sequence, we chose to derive the
unknown TF LTR sequence from LTRs ampliﬁed from genomic DNA
isolated from a white cell pellet from the infected patient at an early
time point after infection (43 days after the estimated date of
infection) (Table 1). Using patient-speciﬁc LTR primers designed
from the available TF sequence of the 50 end of U3 and 30 end of
U5 characterized in the NFL amplicon, we ampliﬁed the 650 bp LTR
Table 1
Characteristics of the samples from the subtype C HIV-1 transmission pair.
ID Statusa EDIb Plasma date DNA datec VLd
Z3618M LR 5/27/09 6/18/09 7/9/09 16,800,000
Z3618F D N/A 7/11/09 20,400
a LR – epidemiologically linked recipient partner, D – donor partner.
b EDI – estimated date of infection.
c DNA date – date of collection of PBMCs from which DNA was extracted.
d VL – viral load – on 6/18/09 for LR, 7/15/09 for D.
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from patient genomic DNA via nested PCR (Fig. 2A). This LTR
amplicon was then cloned into a pBluescript vector that had 15 bp
of complimentary sequence at the ends by a two-piece fusion
reaction using the In-Fusion HD Cloning Kit (Clontech). We then
selected multiple clones and directly Sanger sequenced the entire
LTR in order to infer the LTR sequence for the TF virus, based on the
fact that there is limited diversity at early time points following
infection. The conﬁrmed LTR sequence matched the RNA-derived
NFL TF sequence in all overlapping regions. Only the region of the R
sequence, which is where the primers are located in the NFL
sequence, was newly inferred. This LTR vector was then used to
generate the missing pieces needed to form a full-length IMC from
the available NFL genome amplicons (Fig. 2A).
In-fusion HD cloning of near full-length genomes into TF LTR
In order to generate IMCs using the already ampliﬁed NFL
genomes that were sequenced, we utilized a ligation-independent
cloning strategy using the Clontech In-Fusion HD system to per-
form a three-piece DNA fusion reaction followed by transforma-
tion of high transformation efﬁcient chemically competent
bacteria. Using the previously generated LTR vector as a template,
we performed two independent PCR reactions that generate
1700 bp segments that contain half of the pBluescript vector
and a majority of either U3 or U5 (Fig. 2A). We then generated 9 kb
NFL amplicons amenable to this cloning strategy by reamplifying
from the selected positive ﬁrst round amplicons, using cloning
primers that matched 15 bp sequences at the ends of the two LTR
vector pieces (Fig. 2B). In a 15-min In-Fusion HD cloning reaction,
the three pieces: 1) 1.7 kb, 2) 1.8 kb and 3) 9 kb generated a full-
length molecular clone of the TF virus. For the NT viruses, we
obtained a full-length IMC that is chimeric in the transcribed
genome only for the TF virus R region (Fig. 2C). Thus after a single
round of replication these viruses would contain all sequences
derived from the single genome amplicon except for the R region
of the LTRs.
This process allowed us in a single experiment to clone IMCs for
the amplicon corresponding to the TF virus, as well as the 8 viruses
from the chronically infected epidemiologically-linked donor.
Although clones were generated from PCR reactions from single
HIV genomes, previous methods have led to many PCR-induced
mutations that generated clones which were distinct from the
original single genome derived amplicons and that then required
repair by subsequent mutagenesis protocols (Ochsenbauer et al.,
2012). In contrast, when we sequenced a single representative clone
of the 9 IMCs, we observed that each sequence was identical to that
of its cognate uncloned amplicon. The increase in ﬁdelity that was
observed following cloning, where an individual DNA PCR molecule
out of the population of SGA amplicons is selected, suggests that the
initial ﬁrst round amplicons better reﬂect the sequence of the virus in
the plasma. After additional Q5 ampliﬁcation and subsequent cloning
of amplicons from chronically-infected individuals, we have detected
only a single base change between the sequence of the uncloned
amplicon and the sequence of its cloned genome in more than 25
IMCs, representing approximately 225,000 nucleotides. This estimate
is consistent with experiments performed by NEB where they
detected 2 mismatches in clones following PCR ampliﬁcation with
Q5 in approximately 440,000 nucleotides sequenced (New England
Biolabs).
We hypothesized, based on higher likelihood of sequence
identity to the in vivo virus and the lack of PCR-based recombina-
tion, that IMCs derived by this protocol would yield viruses that
exhibit the true phenotypic characteristics of viruses present in the
diverse quasispecies of a chronically-infected individual, as well as
those that establish infection and ultimately lead to disease.
Particle infectivity of TF and NT variants from a linked heterosexual
transmission pair
All HIV-1 full-length genome TF virus IMCs studied to date have
been functional and replication competent, but the range of
functionality and replication competence of viruses in the plasma
Fig. 1. Highlighter and phylogenetic analysis of HIV-1 near full-length single genome amplicons from a heterosexual epidemiologically-linked transmission pair.
(A) Highlighter analysis of the 25 single genome amplicons from both linked recipient and donor, where the master sequence is set as the TF consensus sequence.
(B) Maximum likelihood tree of the near full-length genomes from a heterosexual epidemiologically-linked transmission pair. In blue are 8 amplicons from the linked
recipient, after transmission. Near full-length amplicons from the donor are shown in red. HIV-1 reference sequences are denoted in black. Viral variants selected for cloning
are indicated by bold letters.
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of a chronically-infected individual has not been fully elucidated.
In order to determine IMC functionality, we generated virus stocks
by transfection of 293T cells with the IMCs. We then determined
the infectious titer of these stocks by infecting Tzm-bl cells, a
CD4þCCR5þ reporter cell line which expresses β-gal following
infection. We determined the relative quantity of virus particles
present in each stock by performing a radio-labeled reverse
transcriptase (RT) assay, assuming consistent RT incorporation
into virions. Particle infectivity ratios were then calculated by
dividing the infectious titer by the RT activity of the stock. The
particle infectivity ratios of the 9 IMC derived viruses are shown in
Fig. 3, and we furthermore demonstrated in three replicate
transfections that all IMCs produced infectious viruses. The range
of infectivities of viruses derived from one individual is more than
one order of magnitude. Moreover, we saw evidence that viruses,
which appear genetically similar on the phylogenetic tree (Fig. 1B),
exhibit similar particle infectivities (Fig. 3). Variants F5, F11, and
the TF, which are derived from the lower branch of the donor tree,
have higher particle infectivities than the viruses (variants F6, F9,
F14, F15, and F21) from the upper branch of the phylogenetic tree.
Variant F8 IMC may be predicted to also have high particle
infectivity, but has a very low infectivity to particle ratio, which
we attribute to a six amino acid deletion at the C-terminal end of
the Gag protein. Thus, in this female to male transmission pair, the
TF that established infection in the new host came from the
branch of more highly infectious viruses, as has been suggested
by others (Parrish et al., 2013; Carlson et al., 2014), although it did
not have the highest infectivity per particle of the donor
quasispecies.
Although the R region of the donor IMCs was derived from the
TF virus LTR, we conﬁrmed, through mutagenesis of the Tar
sequence, by reverting the sequence to its authentic sequence,
that the chimeric nature of the Tar–Tat interaction in these viruses
had no impact on the particle infectivity (Fig. 4). For two viral
varaints, F6 and F9 from the chronically infected donor, we
compared the R sequence of the clone to the known R sequence
of the original single genome amplicon (Fig. 4A). We found that
there were two base pair mismatches in the clone between the R
of the TF LTR used for cloning and the R of the original amplicons
for the two variants. Using site directed mutagenesis we reverted
the two base pairs in the clone, to generate the variants F6 and F9
with their original R sequence, called LTR Mut. We determined the
particle infectivity of the two clones from each variant, differing
only by two base pairs in the Tar sequence (Fig. 4B). We found that
viruses encoding the two base pair change in the R region had
similar virus particle infectivities to their original clone. Although
in both cases a small, less than 2-fold, decrease in infectivity was
observed in the viruses with their cognate R-region, this does not
account for more than one log difference between all the
variant IMCs.
Discussion
We describe here a method for ampliﬁcation and cloning of
HIV-1 full-length genome IMCs that is more cost-effective, has
higher throughput, and is more precise than previous methods.
Using this approach, we have sequenced and cloned the TF virus
from a linked heterosexual transmission pair, as well as multiple
single viral variants from the chronically-infected donor of that
same pair. We have shown that each viral variant, including
both TF and NT variants, produces infectious viruses following
Fig. 2. Diagram for the full-length genome cloning strategy. (A) First, the LTR of the TF is ampliﬁed from genomic DNA and cloned using the In-Fusion system. The LTR vector
is then sequenced and a consensus LTR that matched in sequence to the inferred TF is selected. This LTR vector is used to generate two PCR products used in the ﬁnal cloning
reaction that will encode the missing LTR regions from the NFL amplicon. (B) Previously ampliﬁed single genomes from the recipient and donor partners are selected and
reampliﬁed using cloning primers with sequences that overlap with the ends of the two pieces ampliﬁed from the LTR vector. (C) In a ﬁnal In-Fusion reaction the 9 kb NFL
amplicon is cloned with the 2 LTR vector pieces that complement the missing LTR portions. This process yields a full-length molecular clone that contains all the sequence
information from the NFL amplicon and has the TF R regions.
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transfection. These methods provide evidence that, at least in this
individual, a majority of the genetic variants circulating in the
chronically-infected patient's plasma contain the genetic informa-
tion for a functional virus and that those viruses exhibit a large
range of infectivities. Previous studies have encountered difﬁculty
in cloning functional full-length IMCs for HIV-1 and have therefore
suggested that a signiﬁcant percentage of circulating virus gen-
omes are defective (Parrish et al., 2013; Ndung’u, 2000). Based on
the results presented here, we suggest that this result is due to
PCR-induced mutations accrued using previous methods, and that
full-length RNA genomes circulating in a chronically-infected
patient are predominantly functional. Although research on more
transmission pairs will be required to determine speciﬁc ﬁtness
requirements for transmission, we show that, in this transmission
pair, the TF virus has a higher particle infectivity than a majority of
the viruses circulating in the donor, as suggested previously
(Parrish et al., 2013; Carlson et al., 2014), although it is not the
most infectious.
This study also demonstrates that non-clonally expanded viral
variants from a chronically-infected individual's quasispecies are
infectious and are capable of being high replicators in vitro. Barring
a gross genetic defect, the sampled RNA genomes found in vivo are
functional in vitro. Studies of Enterovirus 71 have shown that
cloning from half genomes and construction of recombinant
genomes versus cloning from full-length PCR amplicons lead to
less functional clones from the same virus stock which again
suggests that laboratory-induced recombination is detrimental to
virus integrity (Lazouskaya et al., 2014). Although viruses such as
HIV-1 can often generate recombinants in vivo, these likely emerge
only after in vivo selection for replication competent viruses and
that in the absence of this selection in vitro constructed chimeras
will more likely produce defective genomes. It will be important in
the future to determine the ﬁtness diversity of viral populations in
HIV-1 infected individuals, since this may both predict transmis-
sibility and the impact of the virus on pathogenesis in that host
(Fraser et al., 2014; Carlson et al., 2014; Prince et al., 2012).
Hepatitis C virus (HCV) is another highly diverse RNA virus
with a large global health burden that suffers from inadequate
laboratory models. The difﬁculty to culture and grow HCV in vitro
stems from a lack of an adequate cell culture system as well as
difﬁculty in generating functional clones. Studies from 1997
showed that HCV clones were non-functional due to PCR-
induced or cloning-induced mutations (Yanagi et al., 1997;
Lohmann and Bartenschlager, 2014). The high ﬁdelity system
described here for generating IMCs could be used in the HCV ﬁeld
to screen a larger number of viral strains for in vitro growth. It
would also allow a better estimate of viral ﬁtness, which would
not rely on restriction based cloning systems or necessitate extra
sequencing costs. Similarly to HIV-1, the genomic instability of
viruses such as Hepatitis C and Respiratory Syncytial virus cre-
ateed obstacles to the construction of infectious clones and could
beneﬁt from accurate ampliﬁcation used in this method (Yanagi et
al., 1997; Hotard et al., 2012). The combination of high ﬁdelity DNA
ampliﬁcation and an enzymatic restriction site independent
method of cloning provides a valuable tool for more detailed
in vitro studies of full-length viral genomes.
Materials and methods
Viral RNA extraction and cDNA synthesis
Viral RNA was extracted from plasma and converted to full-
length cDNA as described previously (Salazar-Gonzalez et al.,
2009). In brief, 140 ml of patient plasma was used to extract viral
RNA using the QIAamp Viral RNA Mini Kit (Qiagen). RNA was
recovered and immediately used to synthesize cDNA using the
SuperScript III Reverse Transcriptase (Life Technologies) enzyme
with an anchor oligo-dT primer (Table 2).
Near full length single genome ampliﬁcation
cDNA was serially diluted in replicates of eight PCR wells and
subjected to nested PCR ampliﬁcation with HIV-speciﬁc primers
that yield a 9-kb fragment beginning at the ﬁrst nucleotide of the
U5 region of the 50 long terminal repeat (LTR) and extending to the
last nucleotide of the R region of the 30 LTR. cDNA dilutions were
tested to identify a dilution where 30% of wells were positive for
ampliﬁcation products (Salazar-Gonzalez et al., 2008). First-round
PCR was performed in 1X Q5 Reaction Buffer, 1X Q5 High GC
Enhancer, 0.35 mM of each dNTP, 0.5 mM of primers 1.U5Cc and
1.3030PlCb (Table 2), and 0.02 U/ml of Q5 Hot Start High-Fidelity
DNA Polymerase (NEB) in a total reaction volume of 25 ml. PCR
conditions for the ﬁrst round are: 98 1C for 30 s, followed by 30
cycles of 98 1C for 10 s, 72 1C for 7.5 min, with a ﬁnal extension of
72 1C for 10 min. 1 ml of ﬁrst round PCR product was then used as
template for the second round PCR, with identical cycling condi-
tions and PCR mix except for the primers. The second round
primers are 2.U5Cd and 2.3030plCb (Table 2). PCR reactions were
then run on a 1% agarose lithium acetate gel at 300 V for 25 min in
order to determine the presence of a 9 kb band.
Fig. 3. Particle infectivities of HIV full-length genome infectious molecular clones
from a linked heterosexual transmission pair. Particle infectivity is measured by the
infectious titer as determined on Tzm-bl cells, divided by the reverse transcriptase
level of the stock measured via radio-labeled RT assays. The particle infectivity of
each virus variant is measured for three separate virus stocks generated from
independent 293T transfections, where error bars represent the standard error of
the mean.
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Fig. 4. Particle infectivities of two viral variants with the chimeric R and original amplicon R sequences. (A) Chimeric R sequences of two single genome amplicons, from
variants F6 and F9 from the donor partner are shown along with the two base pair mismatch found in the Tar region of the clone as compared to the amplicon. The mismatch
is mutated back to the correct Tar sequence via site directed mutagenesis generating a LTR Mut clone for each virus. (B) The particle infectivity of the original clone versus the
LTR Mut is compared for the two viruses and no signiﬁcant difference in infectivity is seen.
Table 2
DNA primers used in the study.
Primer name Sequence (50 - 30) Application Color code (Fig. 2)
Oligo-dT TTTTTTTTTTTTTTTTTTVN cDNA synthesis Not shown
1U5Cc CCTTGAGTGCTCTAAGTAGTGTGTGCCCGTCTGT 1st round NFL PCR Not shown
2U5Cd AGTAGTGTGTGCCCGTCTGTTGTGTGACTC 2nd round NFL PCR Not shown
1.3030plCb ACTACTTAGAGCACTCAAGGCAAGCTTTATTG 1st round NFL PCR Not shown
2.3030plCb TAGAGCACTCAAGGCAAGCTTTATTGAGGCTTA 2nd round NFL PCR Not shown
LTRVec_For GGAAAATCTCTAGCAGTGGCGCCCGAACAGGGA LTR vector – pBluescript piece Not shown
LTRVec_Rev AAATCAACCCATCCACGAGCTCGCCCGCGGTG LTR vector – pBluescript piece Not shown
LTR_For1 TGGATGGGTTGATTTACTC LTR PCR Black
LTR_For2 TGGATGGGTTGATTTACTCCAAGAAAAGGCAAG LTR PCR Red
LTR_Rev1 TGCTAGAGATTTTCCACAC LTR PCR Black
LTR_Rev2 TGCTAGAGATTTTCCACACTACCAAAATGGTCTG LTR PCR Red
3618_Clone_For GGTAACTAGAGATCCCTCAG NFL cloning PCR Cyan
3618_Clone_Rev TGCTTATATGCAGCATCTG NFL cloning PCR Cyan
Vec_1_For TGCTGCATATAAGCAGCTGC NFL cloning vector piece PCR Cyan
Vec_1_Rev CTGTAGCAATGGCAACAACG NFL cloning vector piece PCR Blue
Vec_2_For TTGCCATTGCTACAGGCATCG NFL cloning vector piece PCR Blue
Vec_2_Rev GGATCTCTAGTTACCAGAGTCACAC NFL cloning vector piece PCR Cyan
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LTR ampliﬁcation
White cell pellet from acutely-infected patients were used to
extract genomic DNA using the Qiagen DNeasy Blood and Tissue
kit (Qiagen). Patient-speciﬁc primers determined from the
sequence of their Transmitted/Founder U3 and U5 regions were
generated to directly amplify the entire LTR from genomic DNA
(650 bp) in a nested PCR reaction (Fig. 2A). First round primers,
LTR_For1 and LTR_Rev1, are the ﬁrst 19 bp of U3 and the reverse
complement of the last 19 bp of U5, respectively. First round PCR
was performed in a total reaction volume of 50 ml containing 1X
Q5 Reaction Buffer, 1X GC Enhancer, 0.35 mM of each dNTP, 0.5 mM
of each primer, 0.02 U/ml of Q5 enzyme, and 1 ml of DNA template.
PCR conditions were: 98 1C for 30 s, followed by 30 cycles of 98 1C
for 10 s, 59 1C for 30 s, and 72 1C for 20 s, with a ﬁnal extension of
72 1C for 2 min. 1 ml of ﬁrst round PCR product was then used as
template for the second round PCR in a total volume of 50 ml with
similar components as ﬁrst round, except for the primers. Second
round primers, LTR_For2 and LTR_Rev2, are composed of the ﬁrst
33 bp of patient U3, and the reverse complement of the last 34 bp
of U5. PCR conditions for the second round were: 98 1C for 30 s,
followed by 30 cycles of 98 1C for 10 s and 72 1C for 40 s, with a
ﬁnal extension of 72 1C for 2 min. The amplicons were sized on a
1% agarose lithium acetate gel, and any positive bands were
extracted using the Promega Wizard SV Gel Kit (Promega) and
eluted into 40 ml Nuclease-free water.
Cloning of patient-speciﬁc LTR vector
In order to generate a patient-speciﬁc LTR vector, we generated
a linear vector amplicon containing a bacterial origin of replication
and ampicillin resistance cassette with 15 bp ends that match the
15 bp ends of the patient LTR by PCR ampliﬁcation. Primers for our
vector were LTRVec_For and LTRVec_Rev, where the underlined
sequences represented sequences that overlap with patient spe-
ciﬁc LTR (Table 2). We ampliﬁed the vector piece from the pBlue-
script plasmid using Q5, where PCR conditions were: 98 1C for
30 s, followed by 35 cycles of 98 1C for 10 s and 72 1C for 3 min,
with a ﬁnal extension of 72 1C for 2 min. The 3100 bp vector
piece was gel puriﬁed as described previously. In order to combine
the patient-speciﬁc LTR and the vector piece we used the Clontech
In-Fusion HD cloning kit. Brieﬂy, in a PCR tube, 100 ng of patient-
speciﬁc LTR, 100 ng of vector, and 2 ml of the In-Fusion HD 5X
Enzyme Premix were mixed with nuclease-free water to make a
10 ml reaction. The reaction was incubated at 50 1C for 15 min, and
then held at 4 1C until used for transformation. Stellar competent
cells were transformed as speciﬁed by the manufacturer's protocol
(Clontech). Brieﬂy, competent cells were thawed on ice, 50 ml of
competent cells was transferred to a cold 1.5 ml microcentrifuge
tube, to which 2.5 ml of In-Fusion HD cloning reaction was added
followed by incubation on ice for 30 min. The cells were heat
shocked in a heat block at 42 1C for 1 min, and then returned to ice
for 2 min. A volume of 450 ml of room temperature SOC medium
was then added, and 100 ml of cells plated onto a Luria Broth/agar
plate supplemented with 100 μg/ml ampicillin. The plates were
incubated at 30 1C overnight, after which multiple colonies were
picked and DNA was prepared using the PureYield Plasmid
Miniprep System (Promega). The LTR vector was directly Sanger
sequenced and a consensus LTR that matched in sequence to the
inferred TF was selected.
Full-length amplicon cloning into TF LTR
The previously generated LTR vector is used to generate two
PCR products used in the ﬁnal cloning reaction that will encode
the missing LTR regions from the NFL amplicons (Fig. 2A). In two
separate PCR reactions, we generate the two linear pieces from the
LTR vector. The ﬁrst piece was ampliﬁed by PCR in 1X Q5 Reaction
Buffer, 1X Q5 High GC Enhancer, 0.35 mM of each dNTP, 0.5 mM of
primers Vec_1_For and Vec_1_Rev (Table 2), and 0.02 U/ml of Q5
Hot Start High-Fidelity DNA Polymerase (New England Biolabs) in
a total reaction volume of 25 ml. PCR conditions were: 98 1C for
30 s, followed by 30 cycles of 98 1C for 10 s, 66 1C for 30 s and 72 1C
for 1 min, with a ﬁnal extension of 72 1C for 2 min. The second
vector piece was ampliﬁed using the same reaction mixture except
with primers Vec_2_For and Vec_2_Rev, with the following cycling
conditions: 98 1C for 30 s, followed by 30 cycles of 98 1C for 10 s,
67 1C for 30 s and 72 1C for 1 min, with a ﬁnal extension of 72 1C
for 2 min. The cloning NFL amplicon was derived by reampliﬁca-
tion from the selected ﬁrst round amplicon using cloning primers
3618_Clone_For and 3618_Clone_Rev (Fig. 2B). PCR conditions
were identical to the NFL PCR described previously except for
cycling conditions which were: 98 1C for 30 s followed by 30 cycles
of 98 1C for 10 s, 60 1C for 30 s, and 72 1C for 7.5 min, with a ﬁnal
extension at 72 1C for 10 min. The three PCR products were
independently gel extracted as described previously. In order to
generate the full-length clone, a ﬁnal In-Fusion HD reaction with
the 9 kb NFL cloning amplicon was combined with the 2 LTR
vector pieces, which complement the missing LTR regions, in a
10 ml reaction with 150 ng of each linear gel puriﬁed amplicon, 2 ml
of 5X In-Fusion HD Enzyme Mix, and nuclease free water (Fig. 2C).
The reaction was placed at 50 1C for 15 min, and then kept at 4 1C
until used for transformation. Stellar competent cells (Clontech)
were transformed, and DNA minipreps of colonies were performed
as described above. We conﬁrmed correct cloning by restriction
digest and gel visualization, followed by growth of appropriate
clones in 250 ml Luria Broth plus ampicillin in order to purify with
the PureYield Plasmid Maxiprep System (Promega). All clonal virus
inserts were completely sequenced to conﬁrm identity to the
original NFL amplicon (see below).
Generation of virus stocks and particle infectivity
1.5 mg of proviral plasmid clones were used to transfect 293T
cells with Fugene-HD Transfection reagent (Promega). 293T cell
supernatants were collected 72 h after transfection and clariﬁed by
centrifugation. Virus stocks were then titered on the Tzm-bl
reporter cell line as described previously (Prince et al., 2012;
Claiborne et al., 2014). The virus stocks were also directly analyzed
for RT activity using a radio-labeled RT assay as described
previously (Claiborne et al., 2014; Ostrowski et al., 2006).
Sequencing
All amplicons and clones were directly Sanger sequenced,
aligned, and analyzed as has been described previously (Salazar-
Gonzalez et al., 2009, 2008).
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